secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001567264-26-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics Q1 net loss $2.4M; cash $10.2M; resumes trial enrollment
-------------------------------------------------------------------------------

- Net loss $2.4M for Q1 2026 vs $3.3M in Q1 2025; R&D expenses fell to $1.2M from $2.2M.
- Cash and equivalents $10.2M at March 31, 2026; $60M ATM facility established in March 2026.
- Phase 2 INVINCIBLE-4 TNBC study: 71.4% pCR in INT230-6+SOC arm vs 33% in SOC alone; 44% fewer grade 3+ AEs.
- Swissmedic approved resumption of INVINCIBLE-4 enrollment; plan to resume Q2 2026 and start France sites.
- Decision to resume limited U.S. enrollment in Phase 3 INVINCIBLE-3 soft tissue sarcoma study by Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726426000047/0001567264-26-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726426000047/intensity-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001567264-26-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer